CDK2 and breast carcinoma: In summary, we have validated CDK2 and CDK1 as therapeutic targets in anti-estrogen-sensitive and resistant breast cancer cells by showing G1 and G2/M accumulation after CDK2, CDK1 or combined CDK knockdown, respectively.